Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression

The impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences

(2015) Katalin Lumniczky et al.   CANCER LETTERS

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer

(2015) Jitka Fucikova et al.   Frontiers in Immunology

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

MICA polymorphism: biology and importance in cancer

(2014) D. Chen et al.   CARCINOGENESIS

Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer

(2014) Kei Tomihara et al.   ORAL ONCOLOGY

Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma

(2013) Yuki Homma et al.   ANNALS OF SURGICAL ONCOLOGY

Trial watch

(2012) Erika Vacchelli et al.   OncoImmunology

Current Immunotherapeutic Approaches in Pancreatic Cancer

(2011) Shigeo Koido et al.   Clinical & Developmental Immunology

Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer

(2010) Xiaohui Duan et al.   MEDICAL ONCOLOGY

Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

(2008) Douglas B. Evans et al.   JOURNAL OF CLINICAL ONCOLOGY